• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    3/10/22 12:48:36 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KOD alert in real time by email
    SC 13G/A 1 kod13gafeb22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Kodiak Sciences Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 50015M109 (CUSIP NUMBER) February 28, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 791,565 6. Shared Voting Power* 0 7. Sole Dispositive Power* 2,685,747 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,685,747 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 5.1% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: Kodiak Sciences Inc. Item 1(b) Address of Issuer's Principal Executive Offices: 1200 PAGE MILL RD, PALO ALTO, CALIFORNIA 94304 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. ("Price Associates") Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 50015M109 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: March 10, 2022 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 02/28/2022
    Get the next $KOD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KOD

    DatePrice TargetRatingAnalyst
    12/9/2024$20.00Hold → Buy
    Jefferies
    9/5/2024$3.00Neutral
    H.C. Wainwright
    12/11/2023$2.00Sell
    Goldman
    11/17/2023$7.00 → $12.00Equal Weight → Overweight
    CapitalOne
    7/27/2023$15.00 → $4.00Buy → Neutral
    UBS
    7/25/2023Buy → Neutral
    Chardan Capital Markets
    7/25/2023Neutral → Underweight
    JP Morgan
    7/24/2023Buy → Hold
    Jefferies
    More analyst ratings

    $KOD
    Financials

    Live finance-specific insights

    See more
    • Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

      PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024. To access the webcast, please register at https://edge.media-server.com/mmc/p/q4jdxku4/. A live audio webcast of the event will be available on the "Events and Presentatio

      3/26/24 6:15:00 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

      PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial randomized 559 participants, approximately 80% of whom were enrolled in the United States. The study had two treatment arms: KSI-301 5mg on a flexible long-interval regimen and aflibercept 2mg on a fixed short-interval regimen. In the study, three monthly loading doses were administered to all subje

      2/23/22 6:00:00 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Borgeson John A.

      4 - Kodiak Sciences Inc. (0001468748) (Issuer)

      8/7/24 4:52:43 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chairman and CEO Perlroth Victor

      4 - Kodiak Sciences Inc. (0001468748) (Issuer)

      8/7/24 4:48:10 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Baker Bros. Advisors Lp

      4 - Kodiak Sciences Inc. (0001468748) (Issuer)

      7/2/24 4:49:54 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $KOD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

      SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

      2/14/24 4:23:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

      SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

      1/26/24 11:49:38 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

      SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

      2/14/23 4:19:55 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kodiak Sciences upgraded by Jefferies with a new price target

      Jefferies upgraded Kodiak Sciences from Hold to Buy and set a new price target of $20.00

      12/9/24 7:57:06 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Kodiak Sciences with a new price target

      H.C. Wainwright initiated coverage of Kodiak Sciences with a rating of Neutral and set a new price target of $3.00

      9/5/24 7:49:18 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman resumed coverage on Kodiak Sciences with a new price target

      Goldman resumed coverage of Kodiak Sciences with a rating of Sell and set a new price target of $2.00

      12/11/23 7:49:48 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

      PALO ALTO, Calif., May 1, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that seven scientific presentations on its research programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, being held from May 4-8 in Salt Lake City, Utah. "We are pleased to share new data from Kodiak's research and development efforts at this year's ARVO meeting. This body of work further highlights the power and versatility of Kodiak's ABC® (Antibody Biopolymer Conjugate) platform for

      5/1/25 11:43:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

      PALO ALTO, Calif., March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R&D Day in New York," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation featured scientific, clinical and commercial perspectives and included key retina opinion leaders. It was an important snapshot of where we stood at that time, and where we were going – we called it Kodiak 2.0. Six months later, we are well on track." "It is remarkable that after twenty years of anti-V

      3/27/25 4:01:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

      Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026.GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significancePALO ALTO, Calif., March 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR"). "We randomized more than 250 patients into our GLOW2 Phase 3 study, exceeding our enrollment target," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak. "With its 48-week duration of treatment, all patients are expected to com

      3/10/25 4:39:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Kodiak Sciences Inc

      DEFA14A - Kodiak Sciences Inc. (0001468748) (Filer)

      4/22/25 4:12:08 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Kodiak Sciences Inc

      DEF 14A - Kodiak Sciences Inc. (0001468748) (Filer)

      4/22/25 4:06:57 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Kodiak Sciences Inc

      S-8 - Kodiak Sciences Inc. (0001468748) (Filer)

      3/27/25 4:33:37 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    Leadership Updates

    Live Leadership Updates

    See more
    • Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

      PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr

      9/17/24 4:05:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations

      SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities. “I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive

      12/3/20 11:00:00 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care